Fig. 4

One dose of TAT2-P1/DIG showed rapid-onset prophylactic protection on infected animals. a The protective efficacy of antivirals administrated to mouse lungs 3-day before A(H1N1)pdm09 virus challenge. TAT2-P1/DIG-4 (20 µg/5 µg, n = 10), zanamivir (40 µg, n = 5), or TAT2-P1/PHW (20 µg/5 µg, n = 5) were intratracheally inoculated into corresponding mice 3-day before A(H1N1)pdm09 virus challenge. b The body weight changes of infected mice corresponding to (a). c Viral loads in H1N1-infected mouse lungs treated with TAT2-P1/PHW or TAT2-P1/DIG-4 at 3-day before virus challenge. Viral titers were measured at 2-day post infection by plaque assay. d CD3600 could inhibit delta SARS-CoV-2 replication in hamster lungs. TAT2-P1/CD3600 (50 µg/12.5 µg, CD3600, n = 4) was inoculated to hamster lungs at day 1 before SARS-CoV-2 (Delta) challenge. TAT2-P1/PHW (PHW, n = 5) was given to hamster lungs at day 1 before viral challenges. Lung tissues were collected at 2-day post infection for measuring viral loads by plaque assay. Data were presented as mean ± SD of 4–5 hamsters in each group. * indicates P < 0.05, calculated by the two-tailed Student’s t test